Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration has finalized its decision to call an end to the drug shortage of Eli Lilly's (LLY) ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...